63.30

1.44% 0.90

After Hours: 63.30

Livanova Plc (LIVN)

Overview News Price History Option Chain Financials Discussions Forecast

Livanova Plc stock is traded at $63.30, with a volume of 514.18K. It is up +1.44% in the last 24 hours and down -9.94% over the past month. UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Previous Close:

$62.40

Open:

$63.24

24h Volume:

514.18K

Relative Volume:

0.69

Market Cap:

$3.46B

Revenue:

$1.39B

Net Income/Loss:

$-242.49M

P/E Ratio:

-14.14

EPS:

-4.4759

Net Cash Flow:

$173.29M

1W Performance:

+0.76%

1M Performance:

-9.94%

6M Performance:

+21.08%

1Y Performance:

+58.57%

1-Day Range:

$61.62

$63.65

1-Week Range:

$61.47

$64.18

52-Week Range:

$32.48

$71.92

Livanova Plc Stock (LIVN) Company Profile

Name

Livanova Plc

Sector

Healthcare (1114)

Industry

Medical Devices (143)

Phone

4402033250662

Address

20 EASTBOURNE TERRACE, LONDON

Employee

3,300

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

LIVN's Discussions on Twitter

Compare LIVN vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIVN Livanova Plc	63.30	3.41B	1.39B	-242.49M	173.29M	-4.4759
ABT Abbott Laboratories	104.83	180.82B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	327.65	125.72B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.89	111.16B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	69.78	101.28B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	82.67	47.45B	6.07B	1.06B	1.34B	1.8063

Livanova Plc Stock (LIVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Initiated	KeyBanc Capital Markets	Overweight
Oct-01-25	Downgrade	Goldman	Buy → Neutral
May-20-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Feb-26-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-04-24	Initiated	Goldman	Buy
Sep-17-24	Upgrade	Robert W. Baird	Neutral → Outperform
Mar-20-24	Reiterated	Needham	Buy
Feb-20-24	Upgrade	Mizuho	Neutral → Buy
Sep-06-23	Initiated	HSBC Securities	Hold
Jul-19-23	Initiated	Robert W. Baird	Neutral
Apr-14-23	Initiated	Mizuho	Neutral
Dec-21-22	Initiated	Barclays	Equal Weight
Apr-06-22	Initiated	Wolfe Research	Outperform
Feb-24-22	Upgrade	UBS	Neutral → Buy
Dec-03-21	Initiated	Goldman	Buy
Aug-20-21	Reiterated	Needham	Buy
Jul-20-21	Upgrade	Needham	Hold → Buy
Mar-03-21	Downgrade	Berenberg	Buy → Hold
Jan-05-21	Downgrade	Needham	Buy → Hold
Sep-02-20	Initiated	Robert W. Baird	Outperform
Jun-26-20	Reiterated	Needham	Buy
Oct-30-19	Reiterated	Needham	Buy
Feb-28-19	Reiterated	Needham	Buy
Nov-28-18	Initiated	UBS	Neutral
Aug-02-18	Reiterated	Needham	Buy
Jun-08-18	Initiated	Stifel	Buy
May-31-18	Reiterated	Needham	Buy
Feb-28-18	Reiterated	Needham	Buy

View All

Livanova Plc Stock (LIVN) Latest News

Mar 25, 2026

LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea - Insider Monkey

Mar 25, 2026

LivaNova Broadens OSA Treatment Options With FDA Clearance for aura6000 System - Bitget

Mar 25, 2026

LivaNova Expands OSA Care With FDA-Approved aura6000 System - Yahoo Finance

Mar 25, 2026

LivaNova to Announce First-Quarter 2026 Results - Business Wire

Mar 25, 2026

LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de - AD HOC NEWS

Mar 25, 2026

Mar 24, 2026

LivaNova gains FDA premarket approval for Aura6000 for sleep apnea - MSN

Mar 24, 2026

Mar 23, 2026

LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 23, 2026

Mar 22, 2026

FDA Approves Hypoglossal Nerve Stimulation Device for OSA - Medical Dialogues

Mar 22, 2026

Mar 20, 2026

FDA Approves LivaNova’s aura6000 Neurostimulator for OSA - Sleep Review

Mar 20, 2026

LivaNova aura6000 Obstructive Sleep Apnea treatment granted FDA premarket approval - Med-Tech Insights

Mar 20, 2026

LivaNova eyes 2027 launch of neural sleep apnoea therapy after FDA approval - Medical Device Network

Mar 20, 2026

LivaNova’s Aura6000 FDA Win Reshapes Obstructive Sleep Apnea Opportunity - Sahm

Mar 20, 2026

LivaNova wins FDA approval for sleep apnea nerve device By Investing.com - Investing.com India

Mar 20, 2026

Mar 19, 2026

LivaNova Earns FDA Approval for Neurostim for Sleep Apnea - Medical Product Outsourcing

Mar 19, 2026

LivaNova wins FDA approval for sleep apnea nerve device - Investing.com

Mar 19, 2026

LivaNova gets FDA approval for sleep apnea device without collapse warning - StreetInsider

Mar 19, 2026

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea - The Joplin Globe

Mar 19, 2026

Mar 18, 2026

LivaNova Shares Gain 2% After Strong Q3 Results and Upgraded Full-Year Outlook - MSN

Mar 18, 2026

LivaNova PLC announced that its Aura6000 system has received premarket approval from the U.S. Food and Drug Administration (FDA). The device is designed to treat moderate to severe obstructive sleep apnea. - Bitget

Mar 18, 2026

Patterns Watch: Is LivaNova PLC being accumulated by smart moneyMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Short Interest in LivaNova PLC (NASDAQ:LIVN) Rises By 18.0% - MarketBeat

Mar 17, 2026

LIVN PE Ratio & Valuation, Is LIVN Overvalued - Intellectia AI

Mar 17, 2026

Algert Global LLC Cuts Stock Position in LivaNova PLC $LIVN - MarketBeat

Mar 17, 2026

Mar 16, 2026